MEDIPOST Partners with Teikoku Seiyaku for Osteoarthritis Treatment
MEDIPOST Co., Ltd., a prominent South Korean biotech firm, has successfully entered into a groundbreaking multi-year partnership with Teikoku Seiyaku Co., Ltd. This collaborative effort aims to enhance the commercialization of CARTISTEM®, a revolutionary stem cell therapy aimed at treating knee osteoarthritis in Japan. As part of this agreement, MEDIPOST has secured an upfront payment of US$8 million, signaling a strong commitment to the joint venture in the Japanese market.
Agreement Details and Responsibilities
Under this arrangement, MEDIPOST K.K., the Japanese subsidiary of MEDIPOST, will provide Teikoku Seiyaku with an exclusive license for the sale, distribution, and promotion of CARTISTEM® in Japan. Meanwhile, MEDIPOST will take charge of supplying the necessary drug substance while retaining full manufacturing rights. Beyond the initial payment, there are additional short-term regulatory-based milestones totaling around US$10 million, alongside undisclosed long-term sales-based milestones.
Teikoku Seiyaku's Role in the Partnership
Teikoku Seiyaku Co., Ltd. is set to utilize its extensive network of orthopedic hospitals and clinics to effectively promote and distribute CARTISTEM®. This strategy will aim to accelerate the adoption of CARTISTEM® among patients suffering from moderate to severe knee osteoarthritis. In anticipation of the approval for CARTISTEM®, the company is also planning to bolster its medical representative division to better meet the needs of Japan's healthcare landscape.
The Vision for Patient Care
Japan has a significant population affected by knee osteoarthritis, which presents a substantial unmet medical need. Teikoku Seiyaku’s focus on increasing its orthopedic team to 100 members is a testament to its commitment to addressing this gap in treatment options and improving patient care.
Understanding CARTISTEM® and Its Impact
CARTISTEM® represents an innovative approach in regenerative medicine, specifically tailored for patients with knee osteoarthritis. This allogeneic stem cell therapy has been successfully approved in South Korea and has benefited over 35,000 patients in the last 13 years. With its ability to regenerate cartilage, CARTISTEM® holds potential as a disease-modifying osteoarthritis drug (DMOAD), positioning it as a key player in the treatment landscape.
A Closer Look at the Therapy
Since its introduction, CARTISTEM® has shown promising results in treating knee osteoarthritis. Its mechanism of action involves utilizing stem cells derived from human umbilical cord blood, which are strategically designed to repair damaged cartilage. This innovative solution offers hope for patients seeking alternatives to traditional treatment methods.
About MEDIPOST and Its History
Founded in the year 2000, MEDIPOST has established itself as a leader in the stem cell therapy arena. The company’s expertise spans across various domains, including discovery research, product development, and even contract manufacturing services for cell and gene therapy. The successful launch of CARTISTEM® in 2012 marked a significant milestone, as it became the world’s first regulatory-approved allogeneic human umbilical cord blood-derived mesenchymal stem cell (hUCB-MSC) therapy.
About Teikoku Seiyaku
Incorporated in 1848, Teikoku Seiyaku has committed itself to the mission of creating a world free from pain. Leveraging its cutting-edge transdermal drug delivery technology, the company specializes in developing, manufacturing, and marketing various pharmaceutical products, including innovative approaches to pain management. Recently, Teikoku Seiyaku has formed a sales agreement with ReqMed Company, Ltd. for exclusive distribution rights in Japan for a subcutaneous injection currently undergoing Phase 3 clinical trials.
Frequently Asked Questions
What is the purpose of the partnership between MEDIPOST and Teikoku Seiyaku?
The partnership focuses on the commercialization of CARTISTEM®, a stem cell therapy for knee osteoarthritis in Japan, enhancing its availability to patients.
What is CARTISTEM® and how does it work?
CARTISTEM® is an allogeneic stem cell therapy designed to regenerate cartilage and alleviate symptoms in patients with knee osteoarthritis.
How many patients have received CARTISTEM® therapy to date?
Over 35,000 patients have benefited from the CARTISTEM® therapy since its regulatory approval in South Korea.
What is the expected financial impact of this agreement?
The agreement includes an upfront payment of US$8 million, potential regulatory milestones, and long-term sales-based milestones.
How does Teikoku Seiyaku plan to promote CARTISTEM®?
Teikoku Seiyaku will leverage its network of orthopedic hospitals and clinics and expand its medical sales team to increase the adoption of CARTISTEM®.
